Amir Valizadeh

Dr. Amir Valizadeh

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2022 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
Amir ValizadehAmir Valizadeh
Amir Valizadeh
MMMana Moassefi
Mana Moassefi
ANAmin Nakhostin-Ansari
Amin Nakhostin-Ansari
SASeyed Hossein Hosseini Asl
Seyed Hossein Hosseini Asl
MTMehrnush Saghab Torbati
Mehrnush Saghab Torbati
SFShahriar Faghani
Shahriar Faghani
Objective: To evaluate the performance of the automated abstract screening tool Rayyan. Methods: The records obtained from the search for three systematic reviews were manually screened in four stages. At the end of each stage, Rayyan was used to predict the eligibility score for the remaining records. At two different thresholds (≤2.5 and < 2.5 for exclusion of a record) Rayyan-generated ratings were compared with the decisions made by human reviewers in the manual screening process and the tool’s accuracy metrics were calculated. Results: Two thousand fifty-four records were screened manually, of which 379 were judged to be eligible for full-text assessment, and 112 were eventually included in the final review. For finding records eligible for full-text assessment, at the threshold of < 2.5 for exclusion, Rayyan managed to achieve sensitivity values of 97-99% with specificity values of 19-58%, while at the threshold of ≤2.5 for exclusion it had a specificity of 100% with sensitivity values of 1-29%. For the task of finding eligible reports for inclusion in the final review, almost similar results were obtained. Discussion: At the threshold of < 2.5 for exclusion, Rayyan managed to be a reliable tool for excluding ineligible records, but it was not much reliable for finding eligible records. We emphasize that this study was conducted on diagnostic test accuracy reviews, which are more difficult to screen due to inconsistent terminology.

30 December 2017 in Central European Journal of Immunology
Verified
Journal Article
Open access
PDF file
SBSaeed Bazregari
Saeed Bazregari
GAGholamreza Azizi
Gholamreza Azizi
MTMarzieh Tavakol
Marzieh Tavakol
MAMohammad Hosein Asgardoon
Mohammad Hosein Asgardoon
FKFatemeh Kiaee
Fatemeh Kiaee
AAAsghar Aghamohammadi
Asghar Aghamohammadi
Introduction: Primary immunodeficiency diseases (PIDs) are a heterogeneous group of genetic immune disorders. PID patients suffer from a variety of complications. The aim of this study was to determine the infectious and non-infectious complications among PID patients. Material and methods: This retrospective cohort study was performed on recorded data of 202 PID patients who were diagnosed with eight major categories: common variable immunodeficiency (CVID), X-linked agammaglobulinemia, hyper-IgM syndrome, hyper IgE syndrome, chronic granulomatous disease (CGD), ataxia telangiectasia, hereditary angioedema and leukocyte adhesion deficiency. For all patients, infectious and non-infectious manifestations and laboratory data were collected in a comprehensive questionnaire. Results: Infectious complications were more frequent than non-infectious complications. Pneumonia and otitis media were the main infectious problems in PID patients, especially in patients with antibody deficiencies. Among the non-infectious complications, splenomegaly and hepatomegaly were the most common complications in PID patients, and were more commonly seen in CGD patients than others. Splenomegaly, hepatomegaly and autoimmunity were the most common findings in CVID patients. A significant correlation was observed between diagnostic delay and bronchiectasis in CVID patients (p = 0.042). Conclusions: PID patients are at risk of multiple infectious and non-infectious problems. Timely diagnosis of PIDs not only improves their outcome and quality of life, but also helps prevent these troubling complications.

1 September 2023 in Reviews in the Neurosciences
Verified
Journal Article
Closed access
Amir ValizadehAmir Valizadeh
Amir Valizadeh
MMMana Moassefi
Mana Moassefi
ANAmin Nakhostin-Ansari
Amin Nakhostin-Ansari
SSSoheil Heidari Some’eH
Soheil Heidari Some’eH
HHHossein Hosseini-Asl
Hossein Hosseini-Asl
AMAmir Hossein Memari
Amir Hossein Memari
Autism spectrum disorder (ASD) represents a panel of conditions that begin during the developmental period and result in impairments of personal, social, academic, or occupational functioning. Early diagnosis is directly related to a better prognosis. Unfortunately, the diagnosis of ASD requires a long and exhausting subjective process. We aimed to review the state of the art for automated autism diagnosis and recognition in this research. In February 2022, we searched multiple databases and sources of gray literature for eligible studies. We used an adapted version of the QUADAS-2 tool to assess the risk of bias in the studies. A brief report of the methods and results of each study is presented. Data were synthesized for each modality separately using the Split Component Synthesis (SCS) method. We assessed heterogeneity using the I 2 statistics and evaluated publication bias using trim and fill tests combined with ln DOR. Confidence in cumulative evidence was assessed using the GRADE approach for diagnostic studies. We included 344 studies from 186,020 participants (51,129 are estimated to be unique) for nine different modalities in this review, from which 232 reported sufficient data for meta-analysis. The area under the curve was in the range of 0.71–0.90 for all the modalities. The studies on EEG data provided the best accuracy, with the area under the curve ranging between 0.85 and 0.93. We found that the literature is rife with bias and methodological/reporting flaws. Recommendations are provided for future research to provide better studies and fill in the current knowledge gaps.

1 September 2023 in Journal of Neurosurgical Sciences
Verified
Journal Article
Closed access
MSMohammad Shimia
Mohammad Shimia
AIArad Iranmehr
Arad Iranmehr
Amir ValizadehAmir Valizadeh
Amir Valizadeh
FMFarhad Mirzaei
Farhad Mirzaei
MNMohamad Namvar
Mohamad Namvar
KAKamkar Aeinfar
Kamkar Aeinfar
Article: A placebo-controlled randomized clinical trial of amantadine hydrochloride for evaluating the functional improvement of patients following severe acute traumatic brain injury - Journal of Neurosurgical Sciences 2021 Jun 10 - Minerva Medica - Journals

29 March 2022 in BMC Neurology
Verified
Journal Article
Open access
PDF file
MZMorteza Zarrabi
Morteza Zarrabi
MAMasood Ghahvechi Akbari
Masood Ghahvechi Akbari
MAMan Amanat
Man Amanat
AMAnahita Majmaa
Anahita Majmaa
AMAli Reza Moaiedi
Ali Reza Moaiedi
MAMahmoud Reza Ashrafi
Mahmoud Reza Ashrafi
Introduction: The current multi-center, randomized, double-blind study was conducted among children with cerebral palsy (CP) to assess the safety and efficacy of umbilical cord blood mononuclear cell (UCB-MNC). We performed the diffusion tensor imaging to assess the changes in the white matter structure. Methods: Males and females aged 4 to 14 years old with spastic CP were included. Eligible participants were allocated in 4:1 ratio to be in the experimental or control groups; respectively. Individuals who were assigned in UCB-MNC group were tested for human leukocyte antigen (HLA) and fully-matched individuals were treated with UCB-MNCs. A single dose (5 × 106 /kg) UCB-MNCs were administered via intrathecal route in experimental group. The changes in gross motor function measure (GMFM)-66 from baseline to one year after treatment were the primary endpoints. The mean changes in modified Ashworth scale (MAS), pediatric evaluation of disability inventory (PEDI), and CP quality of life (CP-QoL) were also evaluated and compared between groups. The mean changes in fractional anisotropy (FA) and mean diffusivity (MD) of corticospinal tract (CST) and posterior thalamic radiation (PTR) were the secondary endpoints. Adverse events were safety endpoint. Results: There were 72 included individuals (36 cases in each group). The mean GMFM-66 scores increased in experimental group; compared to baseline (+ 9.62; 95%CI: 6.75, 12.49) and control arm (β: 7.10; 95%CI: 2.08, 12.76; Cohen’s d: 0.62) and mean MAS reduced in individuals treated with UCB-MNCs compared to the baseline (-0.87; 95%CI: -1.2, -0.54) and control group (β: -0.58; 95%CI: -1.18, -0.11; Cohen’s d: 0.36). The mean PEDI scores and mean CP-QoL scores in two domains were higher in the experimental group compared to the control. The imaging data indicated that mean FA increased and MD decreased in participants of UCB-MNC group indicating improvements in white matter structure. Lower back pain, headaches, and irritability were the most common adverse events within 24 h of treatment that were related to lumbar puncture. No side effects were observed during follow-up. Conclusions: This trial showed that intrathecal injection of UCB-MNCs were safe and effective in children with CP. Trial Registration: The study was registered with ClinicalTrials.gov (NCT03795974).

3 October 2021 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
Amir ValizadehAmir Valizadeh
Amir Valizadeh
MMMana Moassefi
Mana Moassefi
EBElham Barati
Elham Barati
MSMohammad Ali Sahraian
Mohammad Ali Sahraian
FAFaezeh Aghajani
Faezeh Aghajani
MFMohammad‐Reza Fattahi
Mohammad‐Reza Fattahi
Background: To evaluate the correlation between T1 hypointense lesions’ mean volume on cerebral MRI with disability level of patients with multiple sclerosis.Methods: We included studies testing the desired outcome in adult patients diagnosed with RRMS or SPMS. In Feb 2021, we searched PubMed, Embase, CENTRAL, and Web of Science to find relevant studies. All included studies were assessed for the risk of bias using a tailored version of the Quality in Prognosis Studies (QUIPS) tool. Extracted correlation coefficients were converted to the Fisher's z scale, and a meta‐analysis using a random‐effects model was performed on the results.Results: We included 27 studies (1919 participants). Meta‐analysis revealed a correlation coefficient of 0.32 (95% CI 0.26–0.37) between T1 hypointense lesions’ mean volume and EDSS score.Discussion: The correlation between T1 hypointense lesions’ mean volume and EDSS was interpreted as low to slightly moderate. The certainty of the evidence was judged to be high.